A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Recruiting · Phase 3 · NCT07412756
Conditions: Depressive Disorder, Major
At a glance
- Research payments reported, 2025
- $188
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 1,000
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Brenipatide (drug), Placebo (drug)
- Dates
- Started 2026-02-09; completion 2028-02
- Results posted
- Not yet
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into four periods as follows: a screening period that will last approximately 1 month, a treatment period with a potential post treatment period that combined will last a minimum of 12 months, and the follow up period that will last approximately 2 months.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $188 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Gustavo Alva, M.D. Psychiatry · Orange, CA
- Rafael M. Conte, MD Psychiatry · Miami, FL
- Yvette I. Sheline, MD Psychiatry · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Life Medical Research Group Corp $83
- Hospital of Univ of Pennsylvania, PA $52
- Atp Clinical Research $52
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.